Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older

Exclusion Criteria

• •Bedridden subjects
• •Previous vaccination against influenza since February 2008.
• •Previous vaccination in the last three years with an investigational adjuvanted candidate seasonal or pandemic influenza vaccine.
• •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
• •Any contra-indication to intramuscular administration of the influenza vaccines.
• •History of hypersensitivity to a previous dose of influenza vaccine.
• •History of allergy or reactions likely to be exacerbated by any component of the vaccine including egg and chicken protein.
• •Acute disease at the time of enrolment. Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. Oral temperature \<37.5°C (99.5°F).